Related Experiment Video

Updated: Jul 25, 2025

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.9K

Practical Recommendations for the Use of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Heart Failure: Insights

Jamshed Dalal1, Praveen Chandra2, Saumitra Ray3

  • 1Kokilaben Dhirubhai Ambani Hospital, Mumbai, India. vidhyan@drreddys.com.

Cardiology and Therapy
|June 29, 2023
PubMed

Insights

Angiotensin receptor-neprilysin inhibitor (ARNI) offers significant benefits for heart failure patients, improving outcomes and quality of life. This paper provides practical recommendations for its use in managing heart failure with reduced, preserved, and improved ejection fraction.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Heart failure presents a substantial public health challenge with high morbidity and mortality rates.
  • Current guideline-directed medical therapy (GDMT) for heart failure is underutilized.
  • Angiotensin receptor-neprilysin inhibitor (ARNI) is a key therapeutic agent for various heart failure types.

Purpose of the Study:

  • To provide practical recommendations for ARNI utilization in heart failure management.
  • To emphasize the role of biomarkers (NT-proBNP, BNP) and echocardiography in diagnosis and monitoring.
  • To improve GDMT implementation and reduce the societal burden of heart failure.

Main Methods:

  • Development of recommendations through six advisory board meetings by Indian cardiologists.
  • Review of clinical trial data demonstrating ARNI's efficacy.
  • Emphasis on diagnostic tools like biomarkers and echocardiography.

Main Results:

  • ARNI effectively reduces cardiovascular death and heart failure hospitalizations.
  • Clinical trials show ARNI enhances patient quality of life.
  • ARNI diminishes the risk of ventricular arrhythmias in heart failure patients.

Conclusions:

  • ARNI is a pivotal treatment for heart failure with reduced, preserved, and improved ejection fraction.
  • Accurate diagnosis and monitoring using biomarkers and echocardiography are crucial.
  • Enhanced ARNI utilization can improve GDMT adherence and patient outcomes.

Keywords:
Angiotensin receptor-neprilysin inhibitorGuideline-directed medical therapyHeart failureHeart failure with preserved ejection fractionHeart failure with reduced ejection fraction

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K
Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

17.9K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
701
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
704
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
11
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
425